AstraZeneca vs Coca-Cola: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and Coca-Cola side by side

1. 1892Coca-Cola

   The Coca-Cola Company Founded

   Asa Griggs Candler incorporated The Coca-Cola Company in Atlanta in 1892 after acquiring rights connected to John Pemberton's original formula.

2. 1899Coca-Cola

   National Bottling Rights Granted

   In 1899, Benjamin F. Thomas and Joseph B. Whitehead secured rights to bottle Coca-Cola across much of the United States. The deal looked less important than the fountain business at first, but it became the foundation of Coca-Cola's physical reach.

3. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

4. 1915Coca-Cola

   Contour Bottle Introduced

   Coca-Cola introduced the contour bottle design in 1915 to make the product recognizable and harder to imitate. At a time when copycat colas were common, the bottle gave consumers a visual and tactile cue that they were buying the real product.

5. 1919Coca-Cola

   Company Sold for $25 Million

   In 1919, the Candler family sold Coca-Cola to a group of investors led by Ernest Woodruff for $25 million. The transaction signaled that Coca-Cola had become a valuable national business rather than a regional success.

6. 1928Coca-Cola

   Olympic Sponsorship Begins

   Coca-Cola began its Olympic sponsorship in 1928, linking the brand to international sport and public celebration. The partnership mattered because it gave Coca-Cola a platform that crossed language and national boundaries.

7. 1985Coca-Cola

   New Coke Reversal

   Coca-Cola introduced New Coke in 1985 after taste tests suggested a sweeter formula could compete more effectively with Pepsi. Consumers rejected the change because the original product had emotional and cultural value beyond flavor.

8. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

9. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

10. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

11. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

12. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

13. 2008Coca-Cola

    Muhtar Kent Becomes CEO

    Muhtar Kent became CEO in 2008 during a period when emerging markets, bottler alignment, and category diversification were becoming more important.

14. 2009Coca-Cola

    Freestyle Fountain System Unveiled

    Coca-Cola unveiled Freestyle in 2009, giving foodservice customers a fountain dispenser with more than 100 beverage choices.

15. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

16. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

17. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

18. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

19. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

20. 2017Coca-Cola

    Topo Chico Joins the Portfolio

    Coca-Cola acquired Topo Chico in 2017, adding a premium sparkling mineral water brand sourced from Cerro del Topo Chico in northern Mexico.

21. 2017Coca-Cola

    James Quincey Becomes CEO

    James Quincey became CEO in 2017 and accelerated the push toward a total beverage strategy. He emphasized revenue growth management, zero-sugar products, refranchising discipline, and fewer but stronger brands.

22. 2019Coca-Cola

    Costa Coffee Acquisition

    Coca-Cola completed the Costa Coffee acquisition in 2019, adding a coffee platform with retail stores, Costa Express vending, for-home formats, and ready-to-drink potential.

23. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

24. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

25. 2021Coca-Cola

    BodyArmor Full Acquisition

    Coca-Cola acquired full control of BodyArmor in 2021 in a transaction valued at about $5.6 billion for the remaining stake. The deal deepened Coca-Cola's position in sports drinks, a category long led by PepsiCo's Gatorade.

26. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

27. 2023Coca-Cola

    $45.8B Revenue

    In FY2023, Coca-Cola reported $45.8 billion in revenue, continuing its recovery from the pandemic-era decline in away-from-home channels.

28. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

29. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

30. 2024Coca-Cola

    $47.1B Revenue

    In FY2024, Coca-Cola reported $47.1 billion in revenue, with organic performance supported heavily by price/mix and concentrate sales timing.

31. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

32. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

33. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

34. 2025Coca-Cola

    $47.9B Revenue and 65,900 Employees

    In FY2025, Coca-Cola reported $47.9 billion in revenue and $13.1 billion in net income. Its 2025 Form 10-K listed about 65,900 company employees at year-end, down from about 69,700 in 2024 because of divestiture activity.

35. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

36. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

37. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

Acquisitions

Questions about AstraZeneca vs Coca-Cola